SelwynSpangenthalMD

PubMed

• 8 citations
  A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
  Courtney Crim, Mark Gotfried, Selwyn Spangenthal, Michael T. Watkins, Amanda Emmett, Catriona Crawford, Charlotte Baidoo, Ramiro Castro-Santamaria> ;BMC Pulmonary Medicine. 2020 May 4
• 4 citations
  ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial Setting.
  Edward Kerwin, Selwyn Spangenthal, Michael T. Zvarich, Valerie Millar, Renu Jain, Kathryn Collison, Raj Sharma> ;Chronic Obstructive Pulmonary Diseases. 2020 Apr 1
• 16 citations
  The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated With Stable Chronic Bronchitis: A Comprehensive Review
  Jill A. Ohar, James F. Donohue, Selwyn Spangenthal> ;Chronic Obstructive Pulmonary Diseases. 2019 Oct 23
• 9 citations
  Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose...
  Faisal Fakih, Selwyn Spangenthal, Barry Sigal, Patrick Darken, Andrea Maes, Shahid Siddiqui, Michael Gillen, Colin Reisner, Ubaldo J. Martin> ;Respiratory Medicine. 2018 May 1
• 4 citations
  A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active...
  Edward Kerwin, Selwyn Spangenthal, Christine Kollar, Earl St Rose, Colin Reisner> ;Respiratory Research. 2018 Mar 5
• Erratum: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using nove...
  Colin Reisner, Leonardo M. Fabbri, Edward Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F. Rabe, Gary T. Ferguson, Fernando J. Martinez, James F. Donohue, Patrick...> ;Respiratory Research. 2017 Aug 21
• 82 citations
  Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
  Fernando J. Martinez, Klaus F. Rabe, Gary T. Ferguson, Leonardo M. Fabbri, Stephen I. Rennard, Gregory Feldman, Sanjay Sethi, Selwyn Spangenthal, Gregory Gottschlich, ...> ;Chest. 2017 Feb 1
• 8 citations
  A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Susp...
  Colin Reisner, Leonardo M Fabbri, Edward M Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F Rabe, Gary T Ferguson, Fernando J Martinez, James F Donohue, Patrick Da...> ;Respiratory Research. 2017 Jan 6
• 13 citations
  Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
  Leonardo M. Fabbri, Edward Kerwin, Selwyn Spangenthal, Gary T. Ferguson, Roberto Rodriguez-Roisin, James Pearle, Sanjay Sethi, Chad Orevillo, Patrick Darken, Earl St R...> ;Respiratory Research. 2016 Sep 2
• 16 citations
  Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
  Craig LaForce, Gregory Feldman, Selwyn Spangenthal, Joerg H Eckert, Michelle Henley, Francesco Patalano, Peter D'Andrea> ;International Journal of Chronic Obstructive Pulmonary Disease. 2016 Jun 8
• Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
  Thomas Siler, Craig LaForce, Farid Kianifard, James Williams, Selwyn Spangenthal> ;International Journal of Chronic Obstructive Pulmonary Disease. 2014 Sep 1
• 22 citations
  Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: A multicenter, randomized study
  Claudia Cote, James Pearle, Amir Sharafkhaneh, Selwyn Spangenthal> ;Pulmonary Pharmacology & Therapeutics. 2009 Feb 1
• 6 citations
  Pneumocystis carinii and cytomegalovirus pneumonia in a previously healthy adult.
  Selwyn Spangenthal, Dennis J. Beer, David R. Snydman, Steven R. Findlay, Ross E. Rocklin, Barry L. Fanburg> ;The American Review of Respiratory Disease. 1982 May 1
• Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
  Vogelmeier, C., Verkindre, C., Cheung, D., Galdiz, J. B., Güçlü, S. Z., Spangenthal, S., Overend, T., Henley, M., Mizutani, G., Zeldin, R. K.> ;Pulm Pharmacol Ther. 2010 Oct
• Join now to see all